Early Day List To Watch: Materion Corporation (NYSE:MTRN), Gas Natural (NYSEMKT:EGAS), Q2 Holdings (NYSE:QTWO), Immunomedics (NASDAQ:IMMU)

Cardtronics Inc. (NASDAQ:CATM) shares fell -4.30% in last trading session and ended the day at $28.90. CATM Gross Margin is 34.20% and its has a return on assets of 5.70%. Cardtronics Inc. (NASDAQ:CATM) quarterly performance is -16.93%.

On 4 February, Cardtronics Inc. (NASDAQ:CATM) reported Q4 EPS of $0.71, $0.01 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $303.3 million versus the consensus estimate of $298.67 million.

Materion Corporation (NYSE:MTRN) ended the last trading day at $24.16. Company weekly volatility is calculated as 4.10% and price to cash ratio as 19.48. Materion Corporation (NYSE:MTRN) showed a weekly performance of -1.35%.

Materion Corporation (NYSE:MTRN) announced March 7, 2016 as the record date for shareholders’ voting at its Annual Meeting to be held in Boston, Massachusetts on May 4, 2016.

On 05 February, Gas Natural Inc. (NYSEMKT:EGAS) shares increased 4.25% and was closed at $8.34. EGAS EPS growth in last 5 year was -30.30%. Gas Natural Inc. (NYSEMKT:EGAS) year to date (YTD) performance is 11.95%.

On 3 February, Gas Natural Inc. (NYSEMKT:EGAS) said that, its dividend will hinge on a strategic plan now due in the second quarter and on commodity prices.

Q2 Holdings, Inc. (NYSE:QTWO) shares fell -17.93% in last trading session and ended the day at $17.94. QTWO Gross Margin is 44.90% and its has a return on assets of -12.70%. Q2 Holdings, Inc. (NYSE:QTWO) quarterly performance is -28.44%.

Q2 Holdings, Inc. (NYSE:QTWO) announced that, it will release its financial results for the fourth quarter and full-year 2015 after market close on 11 February.

Immunomedics Inc. (NASDAQ:IMMU) caters to the Healthcare space. Its weekly performance is 17.02%. On the last day of trading company shares ended up at $2.20. Immunomedics Inc. (NASDAQ:IMMU) distance from 50-day simple moving average (SMA50) is -19.18%.

On 5 February, Immunomedics Inc. (NASDAQ:IMMU) announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease.